Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

Also called NCT05580510

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05580510
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05580510. Randomized; no masking; primary purpose treatment. Start 2023-02-06 (anticipated); primary completion 2023-07-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
Condition
Congenital Heart Disease
Condition
Heart Failure
Intervention (Drug)
Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
Intervention (Drug)
Empagliflozin 10 MG OD
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct05580510
Content hash
61c65dadc8662500c043dad48ea34f23dd8dab65f8f13ef64f787529e3450b22